Five Additional States, Territories Join Medicaid’s Money Follows the Person Program
Medicaid’s Money Follows the Person (MFP) demonstration program, which began in 2008, has helped states transition more than 107,000 people to community settings rather than living in institutional facilities.
What We’re Reading: Premature Death Risk Factors; Pfizer Vaccine Efficacy; CVD Symptom Disparities
People who experienced childhood poverty and other adversities are at greater risk of premature death in adulthood; Pfizer’s COVID-19 vaccine is 73% effective in protecting children younger than 5 years; women experience more symptoms of heart failure and other cardiovascular diseases than men.
What We're Reading: OTC Hearing Aids; Respiratory Devices Failing; Postpartum Medicaid Extended
A new FDA rule will allow hearing aids to be purchased without prescriptions; the FDA has received more than 48,000 reports of faulty Philips respiratory devices between May and July; HHS has extended postpartum Medicaid in Hawaii, Maryland, and Ohio.
Fakhri Reviews Considerations for Second-Line Therapy in DLBCL
Nearly 5 years after approval of the first CAR T-cell therapy, treatment is moving into second line, and patients have more options than ever for diffuse large B-cell lymphoma. How do physicians choose? Bita Fakhri, MD, MPH, hematologist-oncologist at the University of California San Francisco, discusses the process.
What We're Reading: Drug Pricing Debate; Judge Rules Against Walgreens; Predicting TBI Outcomes
Policy observers and industry stakeholders debate the possible spillover effects of Medicare drug pricing reform in the employer-based insurance market; a California federal judge rules Walgreens could be held liable for not investigating suspicious orders of opioids in San Francisco; a blood test performed the day of a traumatic brain injury (TBI) can predict which patients may die and who may survive with a disability.
What We’re Reading: Alzheimer Drug Setback; Rural Health Care Investment; Monkeypox Drug Delivery
Acadia Pharmaceuticals’ pimavanserin (Nuplazid) was not extended by the FDA to include Alzheimer-related psychosis; HHS/Health Resources and Service Administration vow to strengthen rural health care; a new deal has the United States paying $26 million for Siga Technologies’ Tpoxx.